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The high prevalence of hospital readmissions continues to be a challenge for healthcare systems, with implications for the quality of patient care and excess financial costs. The aggregate cost of all-cause 30-day readmissions was more than $52 billion in 2013 in the USA, and nearly one out of every five Medicare patients was re-hospitalised within 30 days of discharge. [1] [2] [3] Consequently, the Centers for Medicare and Medicaid Services (CMS) now publicly report 30-day readmission data and implemented financial penalties for hospitals with excess 30-day readmissions in 2012. 1 4 CMS has expanded the applicable conditions in its readmissions calculations to include hip and knee arthroplasties and coronary artery bypass graft surgery. 4 Postoperative hospital complications are the strongest determinant of 30-day surgical readmission. 5 6 Strategies to reduce 30-day surgical readmission rates at any stage of surgical hospitalisation are increasingly important. Thus, our group has recently begun to study important predictors of 30-day readmission that can be modified. 7 Anaesthetists use different strategies to optimise surgical relaxation, including neuraxial anaesthesia, inhalation anaesthetics, and opioids. 8 9 Dosing of neuromuscular blocking agents (NMBAs) varies widely across anaesthesia providers. 10 Residual neuromuscular block in the post-anaesthesia care unit (PACU) is associated with increased risk for aspiration, inadequate emergence after anaesthesia, delirium, weakness, and delayed PACU discharge.
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The primary aim of this study was to investigate the association of intraoperative administration of NMBA dose and 30-day hospital readmission risk after abdominal surgery. Secondary aims were to determine the association between intraoperative NMBA dose and other quality-of-care indicators, including hospital length of stay (LOS) and costs of index hospitalisation. We hypothesised that intraoperative administration of NMBAs is dose-dependently associated with increased risk for 30-day hospital readmission, prolonged hospital LOS, and increased costs of hospital care in patients undergoing abdominal surgery.
Methods

Data sources and study population
This study was performed at a multidisciplinary, tertiary care hospital in Boston, MA, USA, where more than 40,000 surgical procedures are performed annually. This study was approved by Partners Healthcare Institutional Review Board and written informed consent was waived by the ethics committee. The retrospective analysis was carried out within a consecutively enrolled cohort of adult patients who underwent abdominal surgery under general anaesthesia between 2007 and 2014, as described in other studies. 7 16 Briefly, three databases were accessed for preoperative, intraoperative, and postoperative data. The Anaesthesia Information Management System (AIMS) provides information on preoperative patient status, intraoperative events, administered medication and physiological data from patient monitors (see Supplementary Material: "Data sources"). Preoperative and postoperative patient characteristics were obtained from the Research Patient Data Registry (RPDR), a centralised research registry with data including Charlson Comorbidity Index (CCI) scores, an index of comorbidity severity, 17 18 and readmission diagnoses. Data regarding hospital LOS, costs of hospital care, principal surgical procedures, and discharge destination were retrieved from Enterprise Performance Systems Inc. (EPSi), a performance improvement and financial planning system. CCI and surgical procedures were coded based on the International Statistical Classification of Diseases and Related Health Problems, ninth revision (ICD-9). Surgical procedures were weighed for procedural severity based on risk quantification index for postoperative morbidity.
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Non-depolarising neuromuscular blocking agents
We divided intraoperatively administered NMBA doses (adjusted to body weight) by NMBA-specific ED 95 20 (i.e. the median effective dose required to achieve a 95% reduction in maximal twitch response from baseline), resulting in multiples of ED 95 for NMBAs administered during surgery. 21 Based on the multiples of NMBA ED 95 , the cohort was subdivided into five equally sized quintiles. 21 Of note, these quintiles did not match one, two, three, four and five-fold ED 95 in this observational study. The first quintile comprised patients receiving the lowest NMBA equivalent dose whereas the fifth quintile comprised patients receiving the highest equivalent dose.
Outcomes
The primary outcome was hospital readmission within 30 days after discharge from the index hospitalisation. Readmissions were recorded from six Partners Healthcare hospitals. We evaluated two pre-defined secondary outcomes: hospital LOS and total costs of hospital care. 22 Hospital LOS is defined as the number of days between hospital admission and discharge during the index hospitalisation. Total costs are defined as the sum of direct and indirect costs of patient services. Direct costs contain variable and fixed costs associated with patient services. Indirect costs are fixed costs allocated to direct departments in a step-down structure.
Statistical analysis
Data analysis was performed using STATA (StataCorp LP, version 13.2). Normality was assessed using Shapiro-Wilk analysis. Editor's key points
• The association between intraoperative neuromuscular blocking agent (NMBA) dose and 30-day hospital readmission was retrospectively analysed for a single tertiary medical centre. • Of 13,122 patients undergoing abdominal surgery, administration of a NMBA was dose-dependently associated with higher risk of readmission, length of hospital stay and costs.
• These findings suggest that efforts to reduce doses of NMBAs in abdominal surgery might improve outcomes, which should be validated in prospective studies.
variables as frequency (percentage). Results are presented as adjusted odds ratios (aOR) or incidence rate ratios (aIRR) with 95% confidence intervals (CI) and P-values. A two-tailed P-value of less than 0.05 was considered statistically significant.
For the primary analysis, we carried out a priori defined multivariable logistic regression analysis to test the association between quintiles of intraoperatively administered NMBAs (independent variable) and hospital readmission within 30 days after abdominal surgery (primary outcome). Hospital LOS and costs of hospital care were analysed by negative binomial regression models. 9 Subgroup analyses were performed to investigate the impact of variations in surgical duration, ASA physical status, Charlson comorbidity status, and abdominal surgical subtypes on 30-day hospital readmission. Additionally, we evaluated whether the association between intraoperative NMBA dose and 30-day readmission was modified by major respiratory complications and by inclusion of patients who died in hospital. With an exploratory intent, we examined whether chemical class-related differences (benzylisoquinoline vs aminosteroid-type NMBA) and potency-related differences between cisatracurium, vecuronium and rocuronium modified the association between NMBA ED 95 dose quintile and 30-day readmission by including interaction terms (i.e. "NMBA dose*chemical class" and "NMBA dose*NMBA potency") in the primary analysis (see Supplementary Material: "Sensitivity Analyses"). Additionally, we investigated whether neostigmine dose (quintiles and continuous dose) was associated with 30-day readmission.
Ambulatory surgical procedures
We evaluated whether the association between intraoperative NMBA dose and 30-day readmission was modified by admission type (ambulatory vs inpatient surgical procedure) by building an interaction term between ambulatory status and NMBA ED 95 dose equivalent. Additionally, we determined the predicted readmission rates for patients undergoing ambulatory surgery and exposed to different doses of intraoperative NMBAs.
Results
During the study period, 23,833 adult patients underwent abdominal surgeries under general anaesthesia who were intubated and extubated in the operating room. After eliminating patients with missing core data elements and applying aforementioned inclusion and exclusion criteria, the final cohort size was 13,122 ( Fig. 1) . Tables 1 and 2 show the characteristics of the study cohort. The median (IQR) of ED 95 dose equivalents of administered NMBAs for the first through fifth quintiles were 0 (0-1. Table 3 . Based on histograms of ED 95 dose equivalents per h of surgery of cisatracurium, vecuronium, and rocuronium, administered intraoperative NMBA doses were highly variable across similar surgical procedures ( Fig. 2 and Supplementary Fig. S1 ). To minimize the possibility that NMBA dose simply represents a surrogate of surgical duration, we repeated the regression analysis for short (<120 min) and long (!120 min) surgical duration, and the association between NMBA dose and 30-day readmission observed in our primary analysis remained unchanged (see "Sensitivity analyses").
A total of 1,033 patients (7.9%) were readmitted to a hospital within 30 days after the index hospitalisation. Readmitted patients were more likely to be older (P<0.001) or male (P<0.001), and have higher CCI (P<0.001), and ASA physical status scores (P<0.001) indicating more comorbidities and poorer physical health compared with non-readmitted patients. Readmitted patients had longer surgical procedures (P<0.001), higher risk quantification index for postoperative morbidity (P<0.001), and were more likely to receive intraoperative vasopressors (P<0.001), blood transfusions (P<0.001), and fluid resuscitation (P<0.001). Of readmitted patients, 961 (93%) underwent inpatient surgical procedures and 72 (7%) underwent ambulatory same-day surgeries ( Table 4 ). The 30-day readmission rate increased in a dose-dependent fashion with progressively greater doses of intraoperative NMBAs (P for trend: P<0.001).
A NMBA-specific analysis revealed that the dose-dependent association between NMBA dose and 30-day hospital readmission remained robust for cisatracurium, rocuronium, and vecuronium (z ¼ 5.61, P<0.001; z ¼ 5.40, P<0.001; z ¼ 4.77, P<0.001, respectively). Table 4 ).
Sensitivity analyses
Results from our sensitivity analyses are shown in Table 5 and are described in the Supplementary Material ("Sensitivity Analyses"). The dose-dependent relationship between NMBA and 30-day readmission remained similar regardless of surgical duration, comorbidity status, and ASA physical status scores. Duration of surgery did not modify the unique association between NMBA dose and 30 day readmission. Specifically, the interaction term (short or long duration of surgery x NMBA dose) did not significantly modify the association between NMBA dose quintiles and 30-day readmission (P for interaction¼0.66). Inclusion of patients who died in hospital did not change the dose-dependent effect estimate of intraoperative NMBA dose on 30-day readmission. Diseases of the respiratory system represented 3.4% of principal readmission diagnoses and 47% of secondary readmission diagnoses (Supplementary Tables S1 and S3 Table 5 ). Similar trends in readmission odds were observed among the most common surgical subtypes including liver resection, gastrectomy, colorectal resection, laparoscopic cholecystectomy, and hernia repair ( 
<0.001
Charlson Comorbidity Index (Median, IQR) 
Duration of surgery (min) (Mean, SD) 73 (38) 105 (45) 136 (63) 176 (74) 278 (120) 153 ( 
Multiple imputations
We arrived at a study cohort of 23,421 after performing multiple imputation by chained equations of all missing core data elements (see "Multiple Imputations" in Supplementary Material).
Characteristics of the imputed population are shown in 
Discussion
We found a dose-dependent association between intraoperative NMBA administration and increased odds of 30-day readmission in a large cohort of abdominal surgery patients. Compared with patients who received the lowest NMBA doses, those receiving the highest NMBA doses had substantially increased odds of 30-day readmission, an effect that was magnified in those undergoing ambulatory surgery. The effect was stable among the most common abdominal surgical subtypes, and was not ameliorated by neostigmine reversal. We speculate that residual neuromuscular block contributes to the higher odds of readmission after intraoperative NMBA administration. The strong impact of benzylisoquinolines on the incidence of 30-day readmission supports the view that residual neuromuscular block is a contributing mechanism. We have previously observed a higher incidence of residual neuromuscular block at the end of surgery with cisatracurium compared with rocuronium, despite its favourable pharmacokinetic profile and organ function-independent elimination. 23 Although we did not quantify the degree of postoperative neuromuscular transmission in the PACU, the incidence of residual neuromuscular block has been well-documented in the literature and reported to occur in up to 64% of PACU patients.
11 24 25 Postoperative pulmonary complications might arise after NMBA-induced neuromuscular block from residual effects on the upper airway and pharyngeal function. 26 27 We found a dose-dependent relationship between NMBA dose and 30-day readmission for a readmission diagnosis related to a disease of the respiratory system, a finding that supports the assumption that residual neuromuscular block-induced respiratory impairment can have long-term consequences. Another possibility is that patients receiving higher NMBA doses require higher doses of reversal agents, such as neostigmine, to reverse neuromuscular block. High-dose neostigmine has been shown to be associated with increased risk of postoperative pulmonary complications and postoperative nausea and vomiting, which can increase the risk for readmission after surgery. 28 29 This is supported by our finding that intraoperative neostigmine dose was also associated with a small but significant increase in the risk of 30-day readmission. Furthermore, residual paralysis from intraoperative NMBAs can lead to postoperative functional impairments, such as generalised muscle weakness, [30] [31] [32] [33] leading to increased readmission risk because of complications from immobility. There are several consequences of impaired mobility, including muscle weakness and atrophy, increased risk of thromboembolic events, atelectasis and pneumonia, constipation and reduced gastrointestinal peristalsis, urinary retention and urinary tract infections, skin breakdown, and potential cognitive dysfunction. These conditions are important drivers of 30-day readmission after surgery. 34 35 While residual neuromuscular block can lead to temporary impairment of functional status, the contribution of functional impairments to hospital readmission in this cohort could not be assessed because standardised functional assessments are not routinely obtained in acute care hospitals. However, in the inpatient rehabilitation setting where functional status is routinely documented, function is an important predictor of 30-day readmission in the hip fracture, burn, stroke, medically complex, cancer, and general rehabilitation populations. 36 37 Admission type modified the association between NMBA dose and 30-day readmission. In patients undergoing ambulatory procedures, increasing doses of NMBAs were associated with substantially higher odds of being readmitted compared with patients undergoing inpatient surgery (aOR 2.61 vs 1.22). NMBA residual effects might not be apparent in the early postoperative period when surgical outpatients are discharged, whereas surgical inpatients have the benefit of further inhospital monitoring. It is likely that small but clinically relevant effects of NMBA doses on respiratory and skeletal muscle function are less significant in an inpatient setting where patients receive additional support for activities of daily living.
Our study also demonstrates a large degree of variability in intraoperative NMBA dosing, even within the same abdominal surgical type. Other than the intubating dose, there are no standardised dosing guidelines for intraoperative NMBAs that are generally accepted. Our results suggest that, under the conditions studied, it might be prudent to avoid high-dose NMBAs given the increased odds of 30-day readmission, hospital LOS, and hospital costs after abdominal surgery. Several strategies can be used to reduce the NMBA dose while maintaining adequate neuromuscular relaxation for surgery. 8 First, anaesthesia providers must be attuned to the degree of muscle relaxation required intraoperatively, which varies throughout the procedure by the degree of surgical stimulation, and NMBAs should be titrated accordingly. 38 39 Second, in situations where high-dose NMBAs are unavoidable, antagonizing agents should be strongly considered, and the drug and dose need to be selected and titrated based on train-of-four (TOF) monitoring. 15 Third, alternatives to NMBAs should be considered when appropriate, including the use of epidural anaesthesia and inhaled anaesthetics. 9 40 It is important to interpret the results of this study in the context of the study limitations. This study was retrospective in nature, and though we controlled for multiple patient and intraoperative variables in our analyses, there could be unmeasured variables and residual confounders influencing our results. For instance, data on TOF-ratio in the PACU were not available such that the analysis did not account for postoperative residual paralysis. Additionally, this was a single-centre study at a highly specialised tertiary care hospital. As a result, our findings might not be generalisable to all surgical patients. Finally, as a result of the size of the registry, there were several incomplete patient records. However, utilising multiple imputation analysis, the same trend was evidenced for imputed and non-imputed cohorts.
In summary, our data demonstrate a dose-dependent association between intraoperative NMBA administration in abdominal surgical patients and increased risk of 30-day hospital readmission, longer hospital length of stay, and increased hospital costs. High doses of NMBAs increased the risk of 30-day readmission, particularly in patients undergoing ambulatory surgery, and neostigmine antagonism under the conditions studied did not ameliorate this risk. The use of high-dose NMBAs to facilitate intraoperative conditions during abdominal surgery should be carefully weighed against the potential downstream complications. 
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